1)Jennette JC, et al:2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 65:1-11, 2013 PMID 23045170
2)Csernok E:Anti-neutrophil cytoplasmic antibodies and pathogenesis of small vessel vasculitides. Autoimmun Rev 2:158-164, 2003 PMID 12848957
3)Grayson PC, et al:At the Bench;Neutrophil extracellular traps(NETs)highlight novel aspects of innate immune system involvement in autoimmune diseases. J Leukoc Biol 99:253-264, 2016 PMID 26432901
4)Nakazawa D, et al:Pathogenesis and therapeutic interventions for ANCA-associated vasculitis. Nat Rev Rheumatol 15:91-101, 2019 PMID 30542206
5)Vaglio A, et al:Eosinophilic granulomatosis with polyangiitis(Churg-Strauss);State of the art. Allergy 68:261-273, 2013 PMID 23330816
6)Hashimoto T, et al:Increased circulating cell-free DNA in eosinophilic granulomatosis with polyangiitis;Implications for eosinophil extracellular traps and immunothrombosis. Front Immunol 12:801897, 2021 PMID 35095884
7)Watanabe R, et al:Eosinophilic granulomatosis with polyangiitis;Latest findings and updated treatment recommendations. J Clin Med 12:5996, 2023 PMID 37762936
8)Nishi R, et al:Differential clinicopathologic features of EGPA-associated neuropathy with and without ANCA. Neurology 94:e1726-e1737, 2020 PMID 32217776
9)Lanham JG, et al:Systemic vasculitis with asthma and eosinophilia;A clinical approach to the Churg-Strauss syndrome. Medicine(Baltimore)63:65-81, 1984 PMID 6366453
10)厚生労働科学研究費補助金難治性疾患政策研究事業,他(編):ANCA関連血管炎診療ガイドライン2023.診断と治療社,2023
11)Sada KE, et al:The prevalence, burden of disease, and healthcare utilization of patients with eosinophilic granulomatosis with polyangiitis in Japan;A retrospective, descriptive cohort claims database study. Mod Rheumatol 32:380-386, 2022 PMID 34894250
12)Grayson PC, et al:2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for eosinophilic granulomatosis with polyangiitis. Ann Rheum Dis 81:309-314, 2022 PMID 35110334
13)Guillevin L, et al:Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome. A prospective study in 342 patients. Medicine(Baltimore)75:17-28, 1996 PMID 8569467
14)Guillevin L, et al:The Five-Factor Score revisited;Assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group(FVSG)cohort. Medicine(Baltimore)90:19-27, 2011 PMID 21200183
15)Mukhtyar C, et al:Modification and validation of the Birmingham Vasculitis Activity Score(version 3). Ann Rheum Dis 68:1827-1832, 2009 PMID 19054820
16)Ueno M, et al:Safety and effectiveness of mepolizumab therapy in remission induction therapy for eosinophilic granulomatosis with polyangiitis;A retrospective study. Arthritis Res Ther 24:159, 2022 PMID 35768825
17)Wechsler ME, et al:Benralizumab versus mepolizumab for eosinophilic granulomatosis with polyangiitis. N Engl J Med 390:911-921, 2024 PMID 38393328
18)Nanzer AM, et al:Long-term effectiveness of benralizumab in eosinophilic granulomatosis with polyangiitis. J Allergy Clin Immunol Pract 12:724-732, 2024 PMID 38211889
19)Koike H, et al:Intravenous immunoglobulin for chronic residual peripheral neuropathy in eosinophilic granulomatosis with polyangiitis(Churg-Strauss syndrome);A multicenter, double-blind trial. J Neurol 262:752-759, 2015 PMID 25577176
20)Taniguchi M, et al:Treatment for Churg-Strauss syndrome;Induction of remission and efficacy of intravenous immunoglobulin therapy. Allergol Int 56:97-103, 2007 PMID 17460439
21)Nakamura Y, et al:Low-dose mepolizumab is effective as an add-on therapy for treating long-lasting peripheral neuropathy in patients with eosinophilic granulomatosis with polyangiitis. Mod Rheumatol 32:387-395, 2022 PMID 34910206
22)Comarmond C, et al:Eosinophilic granulomatosis with polyangiitis(Churg-Strauss);Clinical characteristics and long-term followup of the 383 patients enrolled in the French Vasculitis Study Group cohort. Arthritis Rheum 65:270-281, 2013 PMID 23044708